Abrocitinib is a JAK inhibitor which primarily inhibits JAK1 leading to suppression of inflammatory cytokines including interleukins (ILs) 4, 13, and 31 which have been implicated in the pathogenesis of AD.3 This evidence concerns the gene JAK1 and Alzheimer disease.